Compare · ILMN vs SERA
ILMN vs SERA
Side-by-side comparison of Illumina Inc. (ILMN) and Sera Prognostics Inc. (SERA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and SERA operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $28.24B, about 351.8x SERA ($80.3M).
- Over the past year, ILMN is up 94.2% and SERA is down 30.6% - ILMN leads by 124.9 points.
- SERA has been more active in the news (13 items in the past 4 weeks vs 11 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 8 for SERA).
- Company
- Illumina Inc.
- Sera Prognostics Inc.
- Price
- $186.76-1.85%
- $2.04-7.69%
- Market cap
- $28.24B
- $80.3M
- 1M return
- +13.80%
- +8.51%
- 1Y return
- +94.24%
- -30.61%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2021
- News (4w)
- 11
- 13
- Recent ratings
- 25
- 8
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Sera Prognostics Inc.
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest SERA
- Director Phillips Joshua was granted 24,686 shares, increasing direct ownership by 43% to 81,691 units (SEC Form 4)
- Director Mirza Mansoor Raza was granted 24,197 shares, increasing direct ownership by 42% to 81,937 units (SEC Form 4)
- Director Lawrence Sandra Aj was granted 24,702 shares, increasing direct ownership by 150% to 41,175 units (SEC Form 4)
- Director Kamdar Kim P. was granted 25,847 shares, increasing direct ownership by 79% to 58,420 units (SEC Form 4)
- Director Critchfield Gregory C was granted 24,020 shares, increasing direct ownership by 3% to 846,886 units (SEC Form 4)
- Director Capone Mark Christopher was granted 44,379 shares (SEC Form 4)
- Director Barlow Jane F was granted 24,375 shares, increasing direct ownership by 107% to 47,088 units (SEC Form 4)
- PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
- SEC Form 3 filed by new insider Capone Mark Christopher
- Sera Prognostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits